Investigational drug · Phase 2
XKH001Injection
Also called: XKH001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COPD, Atopic Dermatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "XKH001Injection"
First trial start
2025
Aug 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XKH001Injection", any sponsor or status.
Conditions studied
As listed on its trial records.
- COPD
- Atopic Dermatitis
Approved drugs for the same conditions: Atopic dermatitis (eczema) · COPD · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "XKH001Injection" as an intervention, largest first.
Zhejiang Kanova Biopharmaceutical Co., LTDIndustry
NCT07519499 · 75 participants (planned) · Start Apr 1, 2026 · Primary completion Dec 1, 2027
Drug: XKH001Injection; Placebo · For: COPD
- Phase I of XKH001Injection in Healthy AdultsStatus unknown
Beijing Kanova Biopharmaceutical Co., LTDIndustry
NCT05128409 · 35 participants (planned) · Start Mar 7, 2023 · Primary completion Oct 1, 2024
Drug: XKH001 Injection; XKH001Placebo Injection · For: Healthy Adults
Sites: Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
- First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers.
Zhang H, Zheng W, Peng R, et al. · Expert Opin Investig Drugs 2025
Also in development for COPD
- SolrikitugPhase 22 trials
Uniquity One (UNI) · Eosinophilic Esophagitis (EoE), COPD
- HRS-9821Phase 21 trial
Guangdong Hengrui Pharmaceutical Co., Ltd · COPD
- JKN2304Phase 21 trial
Joincare Pharmaceutical Group Industry Co., Ltd · COPD (Chronic Obstructive Pulmonary Disease), COPD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.